News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dendreon Corporation (DNDN) Down As {2} Starts Provenge Analysis



7/1/2010 6:39:47 AM

WSJ -- NEW YORK (Dow Jones)--Dendreon Corp. (DNDN) shares plunged in late trading Wednesday after the U.S. government said it would begin a coverage analysis on whether the company's expensive immunotherapy treatment for prostate cancer is "reasonable and necessary."

Read at Seattle Times
Read at Street Insider
Read at Wall Street Journal
Read at Reuters


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES